Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in advanced or metastatic NSCLC with EGFR or HER2 mutations
NCT05364073Phase 1Active, not recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by ArriVent BioPharma. Primary endpoints: Adverse Events at 36 months and Overall Response Rate at 36 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05364073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364073.